Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.

Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA.

AIDS. 2014 Jan 28;28(3):365-76. doi: 10.1097/QAD.0000000000000093.

2.

The use of nested Polymerase Chain Reaction (nested PCR) for the early diagnosis of Histoplasma capsulatum infection in serum and whole blood of HIV-positive patients.

Dantas KC, Freitas RS, Moreira AP, Silva MV, Benard G, Vasconcellos C, Criado PR.

An Bras Dermatol. 2013 Jan-Feb;88(1):141-3.

3.

Itraconazole: Precautions regarding drug interactions and bioavailability.

Puttick MP, Phillips P.

Can J Infect Dis. 1994 Jul;5(4):179-83.

4.

Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.

Martin EG, Paltiel AD, Walensky RP, Schackman BR.

Value Health. 2010 Dec;13(8):893-902. doi: 10.1111/j.1524-4733.2010.00763.x. Epub 2010 Oct 15.

5.

Histoplasmosis: a clinical and laboratory update.

Kauffman CA.

Clin Microbiol Rev. 2007 Jan;20(1):115-32. Review.

6.

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

US Public Health Service, Infectious Diseases Society of America, Prevention of Opportunistic Infections Working Group.

Infect Dis Obstet Gynecol. 2002;10(1):3-64. No abstract available.

7.

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Connolly P, Wheat LJ, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Goldberg J, Brizendine E, Loebenberg D.

Antimicrob Agents Chemother. 2000 Oct;44(10):2604-8.

8.
10.

Activities of sordarins in murine histoplasmosis.

Graybill JR, Najvar L, Fothergill A, Bocanegra R, de las Heras FG.

Antimicrob Agents Chemother. 1999 Jul;43(7):1716-8.

11.

Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

Connolly P, Wheat J, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Goldberg J, Brizendine E, Loebenberg D.

Antimicrob Agents Chemother. 1999 Feb;43(2):322-8.

12.

Current and emerging azole antifungal agents.

Sheehan DJ, Hitchcock CA, Sibley CM.

Clin Microbiol Rev. 1999 Jan;12(1):40-79. Review.

13.

Treatment of histoplasmosis with MK-991 (L-743,872).

Graybill JR, Najvar LK, Montalbo EM, Barchiesi FJ, Luther MF, Rinaldi MG.

Antimicrob Agents Chemother. 1998 Jan;42(1):151-3.

14.

Histoplasma capsulatum sinusitis.

Butt AA, Carreon J.

J Clin Microbiol. 1997 Oct;35(10):2649-50. Review.

15.

Antifungal prophylaxis during neutropenia and immunodeficiency.

Lortholary O, Dupont B.

Clin Microbiol Rev. 1997 Jul;10(3):477-504. Review.

16.
17.

Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.

Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P.

Antimicrob Agents Chemother. 1997 Feb;41(2):410-4.

19.

History of medical mycology in the united states.

Espinel-Ingroff A.

Clin Microbiol Rev. 1996 Apr;9(2):235-72. No abstract available.

20.

Emerging disease issues and fungal pathogens associated with HIV infection.

Ampel NM.

Emerg Infect Dis. 1996 Apr-Jun;2(2):109-16. Review.

Items per page

Supplemental Content

Write to the Help Desk